OBJECTIVE

To examine the associations between modifiable risk factors and glycemic status changes in individuals with prediabetes.

RESEARCH DESIGN AND METHODS

A total of 10,358 individuals with prediabetes defined by their fasting blood glucose and HbA1c levels from the Health Examinees-Gem study were included in the present study. Modifiable factors, including BMI, abdominal obesity, smoking status, physical activity, alcohol consumption, diet quality, hypertension, and dyslipidemia, were examined to determine their associations with changes in glycemic status during follow-up. In addition, modifiable-factor scores were calculated, and their association with changes in glycemic status was also analyzed.

RESULTS

The median follow-up time for this study was 4 years (range, 1–7 years). BMI ≥25 kg/m2 (adjusted odds ratio [OR] 0.71 [95% CI 0.63–0.79]), abdominal obesity (OR 0.76 [95% CI 0.68–0.86]), heavy drinking (OR 0.74 [95% CI 0.60–0.91]), hypertension (OR 0.71 [95% CI 0.64–0.79]), and dyslipidemia (OR 0.78 [95% CI 0.70–0.85]) were associated with a lower possibility of normoglycemia reversion. BMI ≥25 kg/m2 (OR 1.58 [95% CI 1.29–1.94]), abdominal obesity (OR 1.31 [95% CI 1.11–1.55]), current smoking (OR 1.43 [95% CI 1.07–1.91]), and hypertension (OR 1.26 [95% CI 1.07–1.49]) were associated with a higher probability of type 2 diabetes progression. Having more favorable modifiable factors was also associated with normoglycemia reversion (OR 1.46 [95% CI 1.30–1.64]) and type 2 diabetes progression (OR 0.62 [95% CI 0.49–0.77]).

CONCLUSIONS

More favorable modifiable factors were related to a higher probability of returning to normoglycemia and a lower probability of progression to type 2 diabetes.

Prediabetes is a condition in which blood glucose exceeds normal levels but is still below the threshold for type 2 diabetes (1). This condition has gained more attention because the prevalence is increasing globally (2,3), including in Korea (4,5), and being in this phase puts people at high risk of developing subsequent complications (1,69).

Prediabetes is a critical metabolic condition because it is likely to progress to type 2 diabetes; however, it is potentially reversible (10), and its reversion may be advantageous (1114). Thus, previous studies were conducted to observe the determinants that may be key to the change in prediabetes glycemic status. However, only a few population-based studies have included modifiable factors in their main analysis to determine their association with changes in glycemic status (1416). Moreover, to our knowledge, no studies have examined how modifiable factor scores are associated with glycemic-status changes from prediabetes, even though it has been widely associated with other outcomes.

The Korean Clinical Practice Guidelines for Diabetes suggest that individuals with prediabetes manage their weight by modifying their physical activity and diet. Some recommendations to control blood glucose are also mentioned, including avoiding alcohol consumption, as well as hypertension and dyslipidemia management (17). The World Health Organization stated that tobacco use, physical activity, diet, alcohol consumption, overweight or obesity, and hyperlipidemia may increase the risk of noncommunicable diseases, including diabetes (18). The American Diabetes Association (ADA) also mentioned some lifestyle factors that play a role in the prevention of type 2 diabetes, such as nutrition and physical activity. Furthermore, weight control is also considered an important key in the prevention of type 2 diabetes (10). Therefore, we conducted a study to examine the role of obesity, smoking status, physical activity, alcohol consumption, diet quality, hypertension, and dyslipidemia under the term of “modifiable factors” in prediabetes reversion to normoglycemia, as well as progression to type 2 diabetes, in a Korean population, using both fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) as the markers.

Health Examinees–Gem Study

Health Examinees-Gem (HEXA-G) is a study derived from Health Examinees of the Korean Genome and Epidemiology (KoGES_HEXA). Briefly, KoGES_HEXA is a population-based cohort study that collected epidemiological characteristics, genomic features, and gene–environment interactions of chronic diseases in the Korean population aged 40–69 years. Baseline recruitment was conducted in two phases: phase I was from 2004 to 2008, and phase II was conducted from 2009 to 2013 at 38 health examination centers and training hospitals in eight regions by performing an interview-based questionnaire survey and biological sample collection, both at the same date for each participant. A total of 167,169 participants were recruited at baseline, and 65,642 of them had completed the follow-up survey conducted from 2012 to 2016. After excluding centers that only participated in the pilot study, had different processes for data collection, and participated for less than 2 years, 139,344 people from baseline recruitment were included as HEXA-G participants, and among them, 64,485 were those who had participated in the follow-up survey. Details on participant selection for HEXA-G can be found in Supplementary Figure 1, and other details of the surveys are described elsewhere (1921).

Study Population

This study only included participants from phase II who had completed the follow-up survey to maintain data consistency. Among the participants in the HEXA-G study who had completed their follow-up examination, 26,195 people from phase I were excluded. Individuals with no information on FPG and HbA1c levels at baseline (n = 6 and 10,253, respectively) and no information on FPG and HbA1c levels at follow-up (n = 2 and 9, respectively) were also excluded, leaving 27,041 participants. On the basis of their FPG and HbA1c values, participants were assigned into normoglycemia, prediabetes, and type 2 diabetes groups. Individuals with normoglycemia and type 2 diabetes were excluded (n = 13,762 and 2,439, respectively), as were participants who reported a history of diabetes (n = 482). Finally, 10,358 individuals with prediabetes remained eligible for inclusion in the statistical analysis. A flowchart of participant selection is shown in Fig. 1, and more detailed information on FPG and HbA1c data availability in the HEXA-G can be found in Supplementary Table 1. Although a large number of participants from phase I were excluded, the basic characteristics between the two phases did not show an imbalance in the evaluation of the standardized differences, except for age (Supplementary Table 2). Furthermore, we also confirmed that there was no imbalance found in the characteristics of participants who were included and excluded for the reason of incomplete data on the markers (Supplementary Table 2). This study was approved by the Institutional Review Board (IRB) of Seoul National University (IRB no. E-2111-024-1269).

Figure 1

Flowchart of participant selection.

Figure 1

Flowchart of participant selection.

Close modal

Ascertainment of Prediabetes

Prediabetes was defined by FPG and HbA1c data according to the ADA criteria (1) and history of diabetes diagnosis. The participants were considered to have prediabetes if their FPG level was between 100 and 125 mg/dL, HbA1c was between 5.7% and 6.4% (39–47 mmol/mol), or both (1). Participants who reported a history of diabetes diagnosis by a physician at baseline were not included in the study population, regardless of their FPG and HbA1c levels. The distribution of the glycemic status based on each marker is shown in Supplementary Table 3.

Ascertainment of Outcome

The outcomes of this study included normoglycemia reversion, prediabetes persistence, and type 2 diabetes progression based on participants’ FPG and HbA1c levels according to the ADA criteria at the follow-up survey. Normoglycemia reversion was defined as a normal range of both FPG <100 mg/dL and HbA1c <5.7% (<39 mmol/mol). The presence of either or both impaired fasting glucose (100–125 mg/dL) and elevated HbA1c (5.7–6.4% [39–47 mmol/mol]) was defined as prediabetes persistence. An increased level of FPG ≥126 mg/dL, HbA1c ≥6.5% (≥48 mmol/mol), or both was defined as progression to type 2 diabetes. In addition, participants who reported a history of being diagnosed with diabetes by a physician at follow-up were also considered to have progressed to diabetes, regardless of their FPG and HbA1c levels at follow-up.

Modifiable Risk Factors

The modifiable risk factors in this study were BMI, abdominal obesity, smoking status, physical activity, alcohol consumption, diet quality, hypertension, and dyslipidemia at baseline. Diet quality was assessed using the Diet Quality Index for Koreans (DQI-K), an adapted instrument to examine the overall diet quality of the Korean population that was developed in a previous study (22). It evaluates eight components of diet habit in the analysis: daily protein intake, percentage of energy from fat, percentage of energy from saturated fat, daily cholesterol intake, daily whole-grain intake, daily vegetable intake, daily fruit intake, and daily sodium intake. On the basis of the median value of the total DQI-K score, participants were grouped into good diet quality and poor diet quality groups (22). The definition and categories of each modifiable risk factor are detailed in the Supplementary Table 4.

Modifiable-Factors Score

The modifiable-factors score for this study was derived by summing all the total scores of the following seven parameters: dichotomizing obesity, smoking status, physical activity, alcohol consumption, diet quality, hypertension, and dyslipidemia. Smoking status was categorized as currently smoking and currently not smoking, comprising former smokers and never smokers, because only current smokers showed a significant association with glycemic status change based on the basic characteristics of the population. Alcohol consumption was grouped into nondrinkers to light drinkers and moderate drinkers to heavy drinkers. Instead of BMI, abdominal obesity was used as an indicator of obesity because central obesity is more associated with comorbidity and metabolic syndrome than is BMI (23,24). In addition, a sensitivity analysis was performed by replacing abdominal obesity with BMI as a scoring component and grouping BMI values into <23 kg/m2 and ≥23 kg/m2.

The more favorable category from each component was given a score of 1, and the other category was given a score of 0; thus, the total score ranged from 0 to 7. This approach of dichotomizing the components made it easier for the scoring and interpretation and so for us to understand modifiable risk factors and their association with glycemic status change.

On the basis of tertiles, participants’ total scores were grouped into three categories: participants with scores of 0–4 were categorized into the unfavorable group, those with a score of 5 were in the intermediate group, and those with a score of 6–7 were in the favorable group. The details of the scoring are described in Supplementary Tables 5–7.

Covariates

Potential covariates of sociodemographic factors were included in this study and consisted of sex, age (grouped into 40–49, 50–59, and 60–69 years), education level (middle school or below, high school, and college or above), and income (<200, 200–399, ≥400 per 10,000 Korean Won). Other covariates included baseline FPG, baseline HbA1c (every 0.1 increase), and family history of diabetes.

Statistical Analysis

Multinomial logistic regression analysis with a 95% CI was performed to obtain the odds ratio (OR) for reversion to normoglycemia and progression to type 2 diabetes by setting the prediabetes persistence group as the reference group. Sex (binary), age (continuous), education (categorical), income (categorical), baseline FPG (continuous), baseline HbA1c (continuous), and family history of diabetes (binary) were included as the adjusting variables in the analysis. The analyses of modifiable-factors score included the analysis of continuous score, categorical (unfavorable, intermediate, and favorable), as well as the ordinal category of the score of the number of modifiable factors.

Two additional analyses were then performed. The first was to calculate the standardized differences between participants from phase I and phase II, as well as participants with and without follow-up data; a value >0.2 indicated an imbalance between the two groups (25). The other was a sex-stratified analysis to determine the difference between the ORs of glycemic status changes in men and women along with a heterogeneity test using the Cochran Q and Higgins I2 tests; P < 0.1 or I2 < 50% indicated a significant difference (26). Furthermore, three other sensitivity analyses were performed. The first was done by excluding participants with a follow-up survey of <3 years. Next was the analysis of glycemic status change from prediabetes defined only by FPG. The last was a sensitivity analysis of modifiable-factor scores by substituting abdominal obesity with BMI as one of the scoring components.

All analyses were performed using SPSS, version 26.0 (IBM Company, New York, NY); SAS statistical software, version 9.4 (SAS Institute, Cary, NC); and R Statistical Software, version 4.1.2 (R Foundation for Statistical Computing, Vienna, Austria).

The median follow-up period was 4 years (range, 1–7 years). Among the 10,358 participants, 3,293 (31.8%) had their glycemic status back to normoglycemia and 843 (8.1%) progressed to diabetes. The remaining 6,222 participants (60.1%) maintained their glycemic status at the prediabetes level. The complete results of the baseline characteristics are presented in Table 1.

Table 1

Baseline characteristics and ORs of glycemic status change

VariableN (%)Events at follow-up
Prediabetes persistenceNormoglycemia reversionDiabetes progression
n (%)n (%)OR* (95% CI)n (%)OR* (95% CI)
Sociodemographic factors       
 Sex       
  Men 3,545 (34.2) 2,216 (35.6) 943 (28.6) Reference 386 (45.8) Reference 
  Women 6,813 (65.8) 4,006 (64.4) 2,350 (71.4) 1.32 (1.18–1.46) 457 (54.2) 0.63 (0.53–0.74) 
 Age (mean ± SD) 55.4 ± 7.4 55.7 ± 7.2 54.6 ± 7.7 1.00 (0.99–1.00) 55.7 ± 7.6 0.98 (0.97–0.99) 
 Age category       
  40–49 2,181 (21.1) 1,184 (19.0) 810 (24.6) Reference 187 (22.2) Reference 
  50–59 4,862 (46.9) 2,986 (48.0) 1,504 (45.7) 0.91 (0.81–1.03) 372 (44.1) 0.59 (0.48–0.74) 
  60–69 3,315 (32.0) 2,052 (33.0) 979 (29.7) 0.97 (0.84–1.11) 284 (33.7) 0.56 (0.44–0.71) 
 Education       
  Middle school or less 3,413 (33.1) 2,128 (34.4) 989 (30.2) Reference 296 (35.3) Reference 
  High school 4,126 (40.0) 2,424 (39.2) 1,374 (41.9) 1.22 (1.09–1.38) 328 (39.1) 0.84 (0.69–1.03) 
  College or above 2,768 (26.9) 1,639 (26.5) 915 (27.9) 1.22 (1.06–1.40) 214 (25.5) 0.69 (0.55–0.87) 
 Income category (Korean 10.000 won)       
  <200 3,214 (31.8) 1,935 (31.9) 1,005 (31.1) Reference 274 (33.3) Reference 
  200–399 4,554 (45.0) 2,754 (45.4) 1,435 (44.5) 0.90 (0.80–1.01) 365 (44.3) 0.90 (0.74–1.09) 
  ≥400 2,354 (23.3) 1,382 (22.8) 788 (24.4) 0.98 (0.85–1.13) 184 (22.4) 0.95 (0.74–1.20) 
Modifiable factors       
 BMI, kg/m2       
  <23 3,439 (33.2) 1,894 (30.5) 1,373 (41.7) Reference 172 (20.5) Reference 
  ≥23 6,910 (66.8) 4,323 (69.5) 1,919 (58.3) 0.74 (0.67–0.81) 668 (79.5) 1.38 (1.14–1.67) 
  <18.5 134 (1.3) 68 (1.1) 64 (1.9) 1.10 (0.75–1.61) 2 (0.2) 0.45 (0.11–1.90) 
  18.5–22.9 3,305 (31.9) 1,826 (29.4) 1,309 (39.8) Reference 170 (20.2) Reference 
  23–24.9 2,911 (28.1) 1,801 (29.0) 907 (27.6) 0.78 (0.69–0.88) 203 (24.2) 1.04 (0.82–1.31) 
  ≥25 3,999 (38.6) 2,522 (40.6) 1,012 (30.7) 0.71 (0.63–0.79) 465 (55.4) 1.58 (1.29–1.94) 
 Abdominal obesity       
  No 7,590 (73.3) 4,438 (71.4) 2,636 (80.1) Reference 516 (61.4) Reference 
  Yes 2,758 (26.7) 1,779 (28.6) 655 (19.9) 0.76 (0.68–0.86) 324 (38.6) 1.31 (1.11–1.55) 
 Smoking status       
  Never smokers 7,429 (71.9) 4,393 (70.8) 2,518 (76.6) Reference 518 (61.7) Reference 
  Former smokers 1,743 (16.9) 1,126 (18.1) 454 (13.8) 0.93 (0.77–1.12) 163 (19.4) 0.94 (0.71–1.26) 
  Current smokers 1,164 (11.3) 689 (11.1) 316 (9.6) 0.97 (0.79–1.18) 159 (18.9) 1.43 (1.07–1.91) 
 Smoking pack-year       
  Never smokers 7,429 (72.1) 4,393 (71.0) 2,518 (76.7) Reference 518 (61.8) Reference 
  Light smokers 1,578 (15.3) 982 (15.9) 442 (13.5) 0.96 (0.80–1.15) 154 (18.4) 1.05 (0.79–1.40) 
  Moderate smokers 1,002 (9.7) 625 (10.1) 255 (7.8) 0.94 (0.76–1.17) 122 (14.6) 1.29 (0.94–1.78) 
  Heavy smokers 301 (2.9) 188 (3.0) 69 (2.1) 0.99 (0.71–1.38) 44 (5.3) 1.39 (0.90–2.16) 
 Physical activity, min/week       
  No regular exercise 4,575 (44.3) 2,714 (43.8) 1,492 (45.4) Reference 369 (44.0) Reference 
  <150 1,177 (11.4) 696 (11.2) 383 (11.7) 0.96 (0.83–1.13) 98 (11.7) 1.07 (0.83–1.39) 
  ≥150 4,570 (44.3) 2,790 (45.0) 1,408 (42.9) 0.95 (0.86–1.05) 372 (44.3) 0.98 (0.83–1.16) 
 Alcohol consumption§       
  Nondrinkers 5,941 (57.6) 3,527 (56.9) 1,980 (60.3) Reference 434 (51.7) Reference 
  Light drinkers 2,844 (27.6) 1,689 (27.2) 923 (28.1) 1.03 (0.92–1.15) 232 (27.6) 0.94 (0.77–1.14) 
  Moderate drinkers 739 (7.2) 467 (7.5) 199 (6.1) 0.83 (0.68–1.02) 73 (8.7) 1.02 (0.75–1.40) 
  Heavy drinkers 798 (7.7) 517 (8.3) 180 (5.5) 0.74 (0.60–0.91) 101 (12.0) 1.20 (0.90–1.61) 
 Diet quality       
  Good diet quality 5,342 (51.8) 3,222 (52.0) 1,678 (51.2) Reference 442 (52.7) Reference 
  Poor diet quality 4,971 (48.2) 2,973 (48.0) 1,602 (48.8) 0.93 (0.85–1.02) 396 (47.3) 1.02 (0.87–1.20) 
 Hypertension       
  No 6,880 (66.5) 3,967 (63.8) 2,447 (74.4) Reference 466 (55.5) Reference 
  Yes 3,467 (33.5) 2,249 (36.2) 844 (25.6) 0.71 (0.64–0.79) 374 (44.5) 1.26 (1.07–1.49) 
 Dyslipidemia       
  No 5,768 (55.7) 3,316 (53.3) 2,066 (62.7) Reference 386 (45.8) Reference 
  Yes 4,590 (44.3) 2,906 (46.7) 1,227 (37.3) 0.78 (0.70–0.85) 457 (54.2) 1.17 (0.99–1.37) 
 Hypercholesterolemia       
  No 8,662 (83.6) 5,161 (82.9) 2,804 (85.2) Reference 697 (82.7) Reference 
  Yes 1,696 (16.4) 1,061 (17.1) 489 (14.8) 0.90 (0.79–1.02) 146 (17.3) 1.03 (0.83–1.27) 
 High LDL-C level       
  No 8,929 (86.2) 5,323 (85.6) 2,877 (87.4) Reference 729 (86.5) Reference 
  Yes 1,429 (13.8) 899 (14.4) 416 (12.6) 0.87 (0.76–1.00) 114 (13.5) 0.98 (0.78–1.24) 
 Hypertriglyceridemia       
  No 8,726 (84.2) 5,190 (83.4) 2,906 (88.2) Reference 630 (74.7) Reference 
  Yes 1,632 (15.8) 1,032 (16.6) 387 (11.8) 0.79 (0.69–0.91) 213 (25.3) 1.30 (1.07–1.57) 
 Low HDL-C level       
  No 9,285 (89.6) 5,554 (89.3) 3,011 (91.4) Reference 720 (85.4) Reference 
  Yes 1,073 (10.4) 668 (10.7) 282 (8.6) 0.86 (0.73–1.01) 123 (14.6) 1.31 (1.04–1.66) 
Other factors       
 Family history of diabetes       
  No 8,056 (77.9) 4,810 (77.5) 2,676 (81.4) Reference 570 (67.9) Reference 
  Yes 2,279 (22.1) 1,397 (22.5) 612 (18.6) 0.82 (0.73–0.92) 270 (32.1) 1.53 (1.28–1.82) 
 Baseline FPG (mean ± SD) 96.0 ± 10.2 97.1 ± 9.4 91.7 ± 9.5 0.92 (0.92–0.93) 104.5 ± 10.8 1.07 (1.06–1.08) 
 Baseline HbA1c (mean ± SD) 5.8 ± 0.3 5.8 ± 0.3 5.7 ± 0.2 0.73 (0.71–0.75) 6.0 ± 0.3 1.37 (1.33–1.42) 
DQI components       
 Daily protein intake, % RNI       
  <100 4,958 (48.1) 2,983 (48.2) 1,547 (47.2) Reference 428 (51.1) Reference 
  100–150 3,932 (38.1) 2,369 (38.2) 1,259 (38.4) 0.95 (0.86–1.05) 304 (36.3) 0.90 (0.75–1.07) 
  >150 1,423 (13.8) 843 (13.6) 474 (14.5) 0.94 (0.82–1.09) 106 (12.6) 1.02 (0.80–1.32) 
 Percentage of energy from fat       
  <22.5 9,651 (93.6) 5,814 (93.8) 3,057 (93.2) Reference 780 (93.1) Reference 
  ≥22.5 662 (6.4) 381 (6.2) 223 (6.8) 1.08 (0.89–1.30) 58 (6.9) 1.07 (0.78–1.47) 
 Percentage of energy from saturated fat       
  <% 10,278 (99.7) 6,178 (99.7) 3,267 (99.6) Reference 833 (99.4) Reference 
  ≥% 35 (0.3) 17 (0.3) 13 (0.4) 1.96 (0.84–4.57) 5 (0.6) 1.66 (0.55–5.02) 
 Daily cholesterol intake, mg       
  <300 9,066 (87.9) 5,436 (87.7) 2,895 (88.3) Reference 735 (87.7) Reference 
  ≥300 1,247 (12.1) 759 (12.3) 385 (11.7) 0.94 (0.81–1.09) 103 (12.3) 1.03 (0.81–1.31) 
 Daily whole-grain intake       
  Nondaily 8,615 (83.2) 5,194 (83.5) 2,728 (82.8) Reference 693 (82.2) Reference 
  Daily 1,743 (16.8) 1,028 (16.5) 565 (17.2) 1.03 (0.91–1.17) 150 (17.8) 1.07 (0.87–1.32) 
 Daily vegetable intake, g       
  <200 8,205 (79.6) 4,922 (79.5) 2,612 (79.6) Reference 671 (80.1) Reference 
  ≥200 2,108 (20.4) 1,273 (20.5) 668 (20.4) 0.96 (0.86–1.08) 167 (19.9) 1.03 (0.84–1.25) 
 Daily fruit intake, g       
  <200 6,640 (64.4) 3,997 (64.5) 2,059 (62.8) Reference 584 (69.7) Reference 
  ≥200 3,673 (35.6) 2,198 (35.5) 1,221 (37.2) 0.99 (0.90–1.09) 254 (30.3) 0.90 (0.75–1.07) 
 Daily sodium intake, mg       
  <2,000 4,263 (41.3) 2,553 (41.2) 1,367 (41.7) Reference 343 (40.9) Reference 
  ≥2,000 6,050 (58.7) 3,642 (58.8) 1,913 (58.3) 0.95 (0.87–1.05) 495 (59.1) 1.02 (0.87–1.20) 
 Total DQI-K score (mean ± SD) 3.7 ± 1.3 3.7 ± 1.3 3.7 ± 1.2 0.98 (0.95–1.02) 3.7 ± 1.2 1.01 (0.95–1.08) 
VariableN (%)Events at follow-up
Prediabetes persistenceNormoglycemia reversionDiabetes progression
n (%)n (%)OR* (95% CI)n (%)OR* (95% CI)
Sociodemographic factors       
 Sex       
  Men 3,545 (34.2) 2,216 (35.6) 943 (28.6) Reference 386 (45.8) Reference 
  Women 6,813 (65.8) 4,006 (64.4) 2,350 (71.4) 1.32 (1.18–1.46) 457 (54.2) 0.63 (0.53–0.74) 
 Age (mean ± SD) 55.4 ± 7.4 55.7 ± 7.2 54.6 ± 7.7 1.00 (0.99–1.00) 55.7 ± 7.6 0.98 (0.97–0.99) 
 Age category       
  40–49 2,181 (21.1) 1,184 (19.0) 810 (24.6) Reference 187 (22.2) Reference 
  50–59 4,862 (46.9) 2,986 (48.0) 1,504 (45.7) 0.91 (0.81–1.03) 372 (44.1) 0.59 (0.48–0.74) 
  60–69 3,315 (32.0) 2,052 (33.0) 979 (29.7) 0.97 (0.84–1.11) 284 (33.7) 0.56 (0.44–0.71) 
 Education       
  Middle school or less 3,413 (33.1) 2,128 (34.4) 989 (30.2) Reference 296 (35.3) Reference 
  High school 4,126 (40.0) 2,424 (39.2) 1,374 (41.9) 1.22 (1.09–1.38) 328 (39.1) 0.84 (0.69–1.03) 
  College or above 2,768 (26.9) 1,639 (26.5) 915 (27.9) 1.22 (1.06–1.40) 214 (25.5) 0.69 (0.55–0.87) 
 Income category (Korean 10.000 won)       
  <200 3,214 (31.8) 1,935 (31.9) 1,005 (31.1) Reference 274 (33.3) Reference 
  200–399 4,554 (45.0) 2,754 (45.4) 1,435 (44.5) 0.90 (0.80–1.01) 365 (44.3) 0.90 (0.74–1.09) 
  ≥400 2,354 (23.3) 1,382 (22.8) 788 (24.4) 0.98 (0.85–1.13) 184 (22.4) 0.95 (0.74–1.20) 
Modifiable factors       
 BMI, kg/m2       
  <23 3,439 (33.2) 1,894 (30.5) 1,373 (41.7) Reference 172 (20.5) Reference 
  ≥23 6,910 (66.8) 4,323 (69.5) 1,919 (58.3) 0.74 (0.67–0.81) 668 (79.5) 1.38 (1.14–1.67) 
  <18.5 134 (1.3) 68 (1.1) 64 (1.9) 1.10 (0.75–1.61) 2 (0.2) 0.45 (0.11–1.90) 
  18.5–22.9 3,305 (31.9) 1,826 (29.4) 1,309 (39.8) Reference 170 (20.2) Reference 
  23–24.9 2,911 (28.1) 1,801 (29.0) 907 (27.6) 0.78 (0.69–0.88) 203 (24.2) 1.04 (0.82–1.31) 
  ≥25 3,999 (38.6) 2,522 (40.6) 1,012 (30.7) 0.71 (0.63–0.79) 465 (55.4) 1.58 (1.29–1.94) 
 Abdominal obesity       
  No 7,590 (73.3) 4,438 (71.4) 2,636 (80.1) Reference 516 (61.4) Reference 
  Yes 2,758 (26.7) 1,779 (28.6) 655 (19.9) 0.76 (0.68–0.86) 324 (38.6) 1.31 (1.11–1.55) 
 Smoking status       
  Never smokers 7,429 (71.9) 4,393 (70.8) 2,518 (76.6) Reference 518 (61.7) Reference 
  Former smokers 1,743 (16.9) 1,126 (18.1) 454 (13.8) 0.93 (0.77–1.12) 163 (19.4) 0.94 (0.71–1.26) 
  Current smokers 1,164 (11.3) 689 (11.1) 316 (9.6) 0.97 (0.79–1.18) 159 (18.9) 1.43 (1.07–1.91) 
 Smoking pack-year       
  Never smokers 7,429 (72.1) 4,393 (71.0) 2,518 (76.7) Reference 518 (61.8) Reference 
  Light smokers 1,578 (15.3) 982 (15.9) 442 (13.5) 0.96 (0.80–1.15) 154 (18.4) 1.05 (0.79–1.40) 
  Moderate smokers 1,002 (9.7) 625 (10.1) 255 (7.8) 0.94 (0.76–1.17) 122 (14.6) 1.29 (0.94–1.78) 
  Heavy smokers 301 (2.9) 188 (3.0) 69 (2.1) 0.99 (0.71–1.38) 44 (5.3) 1.39 (0.90–2.16) 
 Physical activity, min/week       
  No regular exercise 4,575 (44.3) 2,714 (43.8) 1,492 (45.4) Reference 369 (44.0) Reference 
  <150 1,177 (11.4) 696 (11.2) 383 (11.7) 0.96 (0.83–1.13) 98 (11.7) 1.07 (0.83–1.39) 
  ≥150 4,570 (44.3) 2,790 (45.0) 1,408 (42.9) 0.95 (0.86–1.05) 372 (44.3) 0.98 (0.83–1.16) 
 Alcohol consumption§       
  Nondrinkers 5,941 (57.6) 3,527 (56.9) 1,980 (60.3) Reference 434 (51.7) Reference 
  Light drinkers 2,844 (27.6) 1,689 (27.2) 923 (28.1) 1.03 (0.92–1.15) 232 (27.6) 0.94 (0.77–1.14) 
  Moderate drinkers 739 (7.2) 467 (7.5) 199 (6.1) 0.83 (0.68–1.02) 73 (8.7) 1.02 (0.75–1.40) 
  Heavy drinkers 798 (7.7) 517 (8.3) 180 (5.5) 0.74 (0.60–0.91) 101 (12.0) 1.20 (0.90–1.61) 
 Diet quality       
  Good diet quality 5,342 (51.8) 3,222 (52.0) 1,678 (51.2) Reference 442 (52.7) Reference 
  Poor diet quality 4,971 (48.2) 2,973 (48.0) 1,602 (48.8) 0.93 (0.85–1.02) 396 (47.3) 1.02 (0.87–1.20) 
 Hypertension       
  No 6,880 (66.5) 3,967 (63.8) 2,447 (74.4) Reference 466 (55.5) Reference 
  Yes 3,467 (33.5) 2,249 (36.2) 844 (25.6) 0.71 (0.64–0.79) 374 (44.5) 1.26 (1.07–1.49) 
 Dyslipidemia       
  No 5,768 (55.7) 3,316 (53.3) 2,066 (62.7) Reference 386 (45.8) Reference 
  Yes 4,590 (44.3) 2,906 (46.7) 1,227 (37.3) 0.78 (0.70–0.85) 457 (54.2) 1.17 (0.99–1.37) 
 Hypercholesterolemia       
  No 8,662 (83.6) 5,161 (82.9) 2,804 (85.2) Reference 697 (82.7) Reference 
  Yes 1,696 (16.4) 1,061 (17.1) 489 (14.8) 0.90 (0.79–1.02) 146 (17.3) 1.03 (0.83–1.27) 
 High LDL-C level       
  No 8,929 (86.2) 5,323 (85.6) 2,877 (87.4) Reference 729 (86.5) Reference 
  Yes 1,429 (13.8) 899 (14.4) 416 (12.6) 0.87 (0.76–1.00) 114 (13.5) 0.98 (0.78–1.24) 
 Hypertriglyceridemia       
  No 8,726 (84.2) 5,190 (83.4) 2,906 (88.2) Reference 630 (74.7) Reference 
  Yes 1,632 (15.8) 1,032 (16.6) 387 (11.8) 0.79 (0.69–0.91) 213 (25.3) 1.30 (1.07–1.57) 
 Low HDL-C level       
  No 9,285 (89.6) 5,554 (89.3) 3,011 (91.4) Reference 720 (85.4) Reference 
  Yes 1,073 (10.4) 668 (10.7) 282 (8.6) 0.86 (0.73–1.01) 123 (14.6) 1.31 (1.04–1.66) 
Other factors       
 Family history of diabetes       
  No 8,056 (77.9) 4,810 (77.5) 2,676 (81.4) Reference 570 (67.9) Reference 
  Yes 2,279 (22.1) 1,397 (22.5) 612 (18.6) 0.82 (0.73–0.92) 270 (32.1) 1.53 (1.28–1.82) 
 Baseline FPG (mean ± SD) 96.0 ± 10.2 97.1 ± 9.4 91.7 ± 9.5 0.92 (0.92–0.93) 104.5 ± 10.8 1.07 (1.06–1.08) 
 Baseline HbA1c (mean ± SD) 5.8 ± 0.3 5.8 ± 0.3 5.7 ± 0.2 0.73 (0.71–0.75) 6.0 ± 0.3 1.37 (1.33–1.42) 
DQI components       
 Daily protein intake, % RNI       
  <100 4,958 (48.1) 2,983 (48.2) 1,547 (47.2) Reference 428 (51.1) Reference 
  100–150 3,932 (38.1) 2,369 (38.2) 1,259 (38.4) 0.95 (0.86–1.05) 304 (36.3) 0.90 (0.75–1.07) 
  >150 1,423 (13.8) 843 (13.6) 474 (14.5) 0.94 (0.82–1.09) 106 (12.6) 1.02 (0.80–1.32) 
 Percentage of energy from fat       
  <22.5 9,651 (93.6) 5,814 (93.8) 3,057 (93.2) Reference 780 (93.1) Reference 
  ≥22.5 662 (6.4) 381 (6.2) 223 (6.8) 1.08 (0.89–1.30) 58 (6.9) 1.07 (0.78–1.47) 
 Percentage of energy from saturated fat       
  <% 10,278 (99.7) 6,178 (99.7) 3,267 (99.6) Reference 833 (99.4) Reference 
  ≥% 35 (0.3) 17 (0.3) 13 (0.4) 1.96 (0.84–4.57) 5 (0.6) 1.66 (0.55–5.02) 
 Daily cholesterol intake, mg       
  <300 9,066 (87.9) 5,436 (87.7) 2,895 (88.3) Reference 735 (87.7) Reference 
  ≥300 1,247 (12.1) 759 (12.3) 385 (11.7) 0.94 (0.81–1.09) 103 (12.3) 1.03 (0.81–1.31) 
 Daily whole-grain intake       
  Nondaily 8,615 (83.2) 5,194 (83.5) 2,728 (82.8) Reference 693 (82.2) Reference 
  Daily 1,743 (16.8) 1,028 (16.5) 565 (17.2) 1.03 (0.91–1.17) 150 (17.8) 1.07 (0.87–1.32) 
 Daily vegetable intake, g       
  <200 8,205 (79.6) 4,922 (79.5) 2,612 (79.6) Reference 671 (80.1) Reference 
  ≥200 2,108 (20.4) 1,273 (20.5) 668 (20.4) 0.96 (0.86–1.08) 167 (19.9) 1.03 (0.84–1.25) 
 Daily fruit intake, g       
  <200 6,640 (64.4) 3,997 (64.5) 2,059 (62.8) Reference 584 (69.7) Reference 
  ≥200 3,673 (35.6) 2,198 (35.5) 1,221 (37.2) 0.99 (0.90–1.09) 254 (30.3) 0.90 (0.75–1.07) 
 Daily sodium intake, mg       
  <2,000 4,263 (41.3) 2,553 (41.2) 1,367 (41.7) Reference 343 (40.9) Reference 
  ≥2,000 6,050 (58.7) 3,642 (58.8) 1,913 (58.3) 0.95 (0.87–1.05) 495 (59.1) 1.02 (0.87–1.20) 
 Total DQI-K score (mean ± SD) 3.7 ± 1.3 3.7 ± 1.3 3.7 ± 1.2 0.98 (0.95–1.02) 3.7 ± 1.2 1.01 (0.95–1.08) 

OR in bold denote statistical significance at the P < 0.05 level.

RNI, reference nutrient intake.

*

OR adjusted for age (continuous), education, income, baseline FPG (continuous), baseline HbA1c (continuous), and family history of diabetes.

Abdominal obesity was defined as a waist circumference ≥90 cm for men and ≥85 cm for women.

Smoking pack-year was grouped into light (0, 1–20 pack-years), moderate (20.1–40 pack-years), and heavy smokers (>40 pack-years).

§

Alcohol consumption was categorized into light (<0.1–19.9 g/day for men and 0.1–9.9 g/day for women), moderate (20–39.9 g/day for men and 10–19.9 g/day for women), or heavy drinkers (≥40 g/day for men and ≥20 g/day for women).

Diet quality was considered good if the DQI-K score was 0–3 and poor if the score was 4–9.

Normoglycemia Reversion

Compared with men, women appeared to have a higher probability of normoglycemia reversion (OR 1.32, 95% CI 1.18–1.46). Similarly, people with higher education (OR 1.22, 95% CI 1.09–1.38 for high school level; and OR 1.22, 95% CI 1.06–1.40 for college or above level) were more likely to have normoglycemia reversion. Furthermore, among the modifiable factors, BMI ≥25 kg/m2 (OR 0.71, 95% CI 0.63–0.79), abdominal obesity (OR 0.76, 95% CI 0.68–0.85), heavy drinking (OR 0.74, 95% CI 0.60–0.91), hypertension (OR 0.71, 95% CI 0.64–0.79), and dyslipidemia (OR 0.78, 95% CI 0.70–0.85) lowered the probability of normoglycemia reversion. Similarly, a family history of diabetes (OR 0.82, 95% CI 0.73–0.92), higher baseline FPG (OR 0.92, 95% CI 0.91–0.93), and higher baseline HbA1c (OR 0.73, 95% CI 0.71–0.71) also decreased the probability.

Type 2 Diabetes Progression

In the results of the sociodemographic factors, a lower probability of type 2 diabetes progression was found in women (OR 0.63 [95% CI 0.96–0.99], compared with men) and older age categories (OR 0.59 [95% CI 0.48–0.73] for the 50–59 years age group; and OR 0.56 [95% CI 0.44–0.71] for the 60–69 years age group) and participants with an education level of college or above (OR 0.69, 95% CI 0.54–0.87). Furthermore, among the modifiable-factors analyses results, a higher risk of type 2 diabetes progression was observed with BMI ≥25 kg/m2 (OR 1.58, 95% CI 1.29–1.94), abdominal obesity (OR 1.31, 95% CI 1.11–1.55), current smokers (OR 1.43, 95% CI 1.07–1.91), and hypertension (OR 1.26, 95% CI 1.07–1.49). Similarly, a family history of diabetes (OR 1.53, 95% CI 1.28–1.82), increase in baseline FPG (OR 1.07, 95% CI 1.06–1.08), and every 0.1 increase in baseline HbA1c (OR 1.37, 95% CI 1.33–1.42) increased the risk of type 2 diabetes progression.

Modifiable-Factors Score

The results from the scoring analyses are presented in Table 2, which shows that along with the increase in modifiable-factors score, the probability for normoglycemia reversion increased (OR 1.15, 95% CI 1.10–1.19) and type 2 diabetes progression decreased (OR 0.88, 95% CI 0.82–0.93). The median score was 5, comprising 30.9% of the participants, and those who scored lower were less likely to have normoglycemia reversion and likely to have type 2 diabetes progression, whereas the opposite trend was observed for those who scored higher. Similar results were found in the categorical analysis, where the favorable group was more likely to regress to normoglycemia (OR 1.46, 95% CI 1.30–1.64) and less likely to progress to type 2 diabetes (OR 0.62, 95% CI 0.49–0.77).

Table 2

Associations between modifiable-factors score and glycemic status change

VariableN (%)Events at follow-up
Prediabetes persistenceNormoglycemia reversionDiabetes progression
n (%)n (%)OR* (95% CI)n (%)OR* (95% CI)
Modifiable-factors score (continuous; mean ± SD) 4.6 ± 1.3 4.5 ± 1.3 4.9 ± 1.2 1.15 (1.10–1.19) 4.1 ± 1.3 0.88 (0.82–0.93) 
Modifiable-factors category       
 Unfavorable group 4,502 (43.8) 2,850 (46.2) 1,162 (35.6) Reference 490 (58.5) Reference 
 Intermediate group 3,049 (29.7) 1,814 (29.4) 1,013 (31.1) 1.19 (1.06–1.33) 222 (26.5) 0.81 (0.67–0.98) 
 Favorable group 2,717 (26.5) 1,507 (24.4) 1,085 (33.3) 1.46 (1.30–1.64) 125 (14.9) 0.62 (0.49–0.77) 
Modifiable-factors score, n       
 0 22 (0.2) 17 (0.3) 3 (0.1) 0.38 (0.10–1.39) 2 (0.2) 0.82 (0.18–3.78) 
 1 110 (1.1) 71 (1.2) 13 (0.4) 0.47 (0.25–0.90) 26 (3.1) 1.90 (1.10–3.30) 
 2 487 (4.7) 312 (5.1) 109 (3.3) 0.78 (0.61–1.01) 66 (7.9) 1.32 (0.94–1.86) 
 3 1,322 (12.9) 859 (13.9) 312 (9.6) 0.78 (0.66–0.92) 151 (18.0) 1.20 (0.94–1.53) 
 4 2,561 (24.9) 1,591 (25.8) 725 (22.2) 0.90 (0.79–1.02) 245 (29.3) 1.20 (0.97–1.49) 
 5 3,049 (29.7) 1,814 (29.4) 1,013 (31.1) Reference 222 (26.5) Reference 
 6 2,147 (20.9) 1,217 (19.7) 827 (25.4) 1.19 (1.05–1.35) 103 (12.3) 0.77 (0.59–1.00) 
 7 570 (5.6) 290 (4.7) 258 (7.9) 1.39 (1.14–1.70) 22 (2.6) 0.71 (0.43–1.18) 
VariableN (%)Events at follow-up
Prediabetes persistenceNormoglycemia reversionDiabetes progression
n (%)n (%)OR* (95% CI)n (%)OR* (95% CI)
Modifiable-factors score (continuous; mean ± SD) 4.6 ± 1.3 4.5 ± 1.3 4.9 ± 1.2 1.15 (1.10–1.19) 4.1 ± 1.3 0.88 (0.82–0.93) 
Modifiable-factors category       
 Unfavorable group 4,502 (43.8) 2,850 (46.2) 1,162 (35.6) Reference 490 (58.5) Reference 
 Intermediate group 3,049 (29.7) 1,814 (29.4) 1,013 (31.1) 1.19 (1.06–1.33) 222 (26.5) 0.81 (0.67–0.98) 
 Favorable group 2,717 (26.5) 1,507 (24.4) 1,085 (33.3) 1.46 (1.30–1.64) 125 (14.9) 0.62 (0.49–0.77) 
Modifiable-factors score, n       
 0 22 (0.2) 17 (0.3) 3 (0.1) 0.38 (0.10–1.39) 2 (0.2) 0.82 (0.18–3.78) 
 1 110 (1.1) 71 (1.2) 13 (0.4) 0.47 (0.25–0.90) 26 (3.1) 1.90 (1.10–3.30) 
 2 487 (4.7) 312 (5.1) 109 (3.3) 0.78 (0.61–1.01) 66 (7.9) 1.32 (0.94–1.86) 
 3 1,322 (12.9) 859 (13.9) 312 (9.6) 0.78 (0.66–0.92) 151 (18.0) 1.20 (0.94–1.53) 
 4 2,561 (24.9) 1,591 (25.8) 725 (22.2) 0.90 (0.79–1.02) 245 (29.3) 1.20 (0.97–1.49) 
 5 3,049 (29.7) 1,814 (29.4) 1,013 (31.1) Reference 222 (26.5) Reference 
 6 2,147 (20.9) 1,217 (19.7) 827 (25.4) 1.19 (1.05–1.35) 103 (12.3) 0.77 (0.59–1.00) 
 7 570 (5.6) 290 (4.7) 258 (7.9) 1.39 (1.14–1.70) 22 (2.6) 0.71 (0.43–1.18) 

OR in bold denote statistical significance at the P < 0.05 level.

*

OR adjusted for age (continuous), education, income, baseline FPG (continuous), baseline HbA1c, and family history of diabetes.

All modifiable-factors score is the sum of abdominal obesity, smoking status, physical activity, alcohol consumption, diet quality, hypertension, and dyslipidemia scores.

All factors score was divided into three groups on the basis of tertiles scores. Scores of 0–4 were categorized as unfavorable, 5 as intermediate, and 6–7 as favorable.

Figure 2A shows the adjusted ORs of each component of the modifiable score for glycemic status change and indicates that of all components, hypertension (OR 1.42 [95% CI 1.28–1.58] for having hypertension compared with no presence of hypertension) had the highest probability of normoglycemia reversion and smoking status (OR 0.69 [95% CI 0.54–0.87] for currently smoking compared with currently not smoking) were associated with the highest risk of type 2 diabetes progression. Although the figure indicates that some components, such as physical activity and diet quality, have similar ORs for normoglycemia reversion and type 2 diabetes progression, Fig. 2B shows that there are differences in the distribution of people with favorable modifiable scores for each component. The higher the modifiable-factors score, the larger is the proportion of people with higher scores for each component (Fig. 2B).

Figure 2

ORs of glycemic status change of each modifiable-factors score component and distribution of participants with a favorable score in each component. A) ORs of glycemic status change of each modifiable-factors score component adjusted for age (continuous), education, income, baseline FPG (continuous), baseline HbA1c (continuous), and family history of diabetes. B) Distribution of participants with a favorable score in each component (i.e., participants who were given a score of 1 in each scoring component): no abdominal obesity: 97.1%, 83.3%, 52.2%; currently not smoking: 99.0%, 44.3%, 28.2%; 150 min/week of physical activity: 70.7%, 44.3%, 28.2%; nondrinker to moderate drinker of alcohol: 97.7%, 93.1%, 72.1%; good diet quality: 76.8%, 48.0%, 31.2%; no hypertension: 92.6%, 73.9%, 45.7%; and no dyslipidemia: 87.0%, 62.9%, 31.8% for the favorable group, intermediate group, and unfavorable groups, respectively.

Figure 2

ORs of glycemic status change of each modifiable-factors score component and distribution of participants with a favorable score in each component. A) ORs of glycemic status change of each modifiable-factors score component adjusted for age (continuous), education, income, baseline FPG (continuous), baseline HbA1c (continuous), and family history of diabetes. B) Distribution of participants with a favorable score in each component (i.e., participants who were given a score of 1 in each scoring component): no abdominal obesity: 97.1%, 83.3%, 52.2%; currently not smoking: 99.0%, 44.3%, 28.2%; 150 min/week of physical activity: 70.7%, 44.3%, 28.2%; nondrinker to moderate drinker of alcohol: 97.7%, 93.1%, 72.1%; good diet quality: 76.8%, 48.0%, 31.2%; no hypertension: 92.6%, 73.9%, 45.7%; and no dyslipidemia: 87.0%, 62.9%, 31.8% for the favorable group, intermediate group, and unfavorable groups, respectively.

Close modal

Additional and Sensitivity Analyses

Of all participants in the HEXA-G recruited from phase II, only 35,570 (50.6%) had follow-up data; however, the comparisons between those with and without follow-up data using standardized differences did not show a noteworthy imbalance (Supplementary Table 2). Results from stratified analysis by sex showed that most of the ORs of changes in glycemic status were not different between men and women (Supplementary Tables 8 and 9). The variable that showed a significant difference was the educational level of college in normoglycemia reversion. The sensitivity analysis, after excluding participants with a follow-up time of <3 years, showed consistent results (Supplementary Table 10). The results of sensitivity analysis using only FPG to define the glycemic status appeared to be similar to the main analysis in terms of significance, except for sex and hypertension, which showed nonsignificant associations with diabetes progression (Supplementary Table 11). Furthermore, the result of the analysis after replacing abdominal obesity with BMI in the scoring component was also comparable to the main result of the modifiable-factor score (Supplementary Table 12).

Among 27,041 participants from the original study with all the needed information on FPG and HbA1c, 10,358 participants (37.8%) were defined as having prediabetes and were included in our study. Using only FPG, 4,443 patients (16.4%) were identified with prediabetes. Meanwhile, if only HbA1c was used as the marker, 8,976 patients (33.2%) with prediabetes were identified. Therefore, using both markers increased the sensitivity of detecting individuals with prediabetes.

The results of this study suggest that most of the participants (60.1%) managed to maintain their plasma glucose levels within the prediabetes range for 4 years. Among the rest, more people showed their glycemic status regressed to normoglycemia (31.8%) than those who progressed to type 2 diabetes (8.2%). The prevalence of blood glucose transition differed depending on the indicator used. Nevertheless, previous studies analyzing prediabetes changes using cutoff points from ADA reported similar findings, suggesting that cases of regression from prediabetes to normoglycemia are more frequent (27).

In this study, older adults with prediabetes were less likely to have type 2 diabetes progression. These results were comparable with those of previous studies that examined the progression of type 2 diabetes among older adults with prediabetes (28,29). Findings from these two studies suggest that the conversion rate of diabetes progression is lower than that of normoglycemia reversion, mortality, and prediabetes persistence. Our study showed a significant negative association with type 2 diabetes progression and an inverse association with normoglycemia reversion (although no significance was found), suggesting that, rather than a change in glycemic status, older people were more likely to remain in prediabetes.

Higher education was associated with a higher possibility of normoglycemia reversion and a lower risk of developing type 2 diabetes. The sex-stratified analysis (Supplementary Table 8) indicated that the association with normoglycemia reversion was only significant among women. Although it is not clear, this finding could be explained by the effect of education on normoglycemia reversion that might be confounded by engagement in a healthy lifestyle. Particularly in our study, education was associated with the modifiable-factors score among women but not men (Supplementary Table 13). The difference then may cause the probability of normoglycemia reversion to appear disparate between men and women.

This study indicated that among the modifiable risk factors, obesity, heavy alcohol consumption, hypertension, and dyslipidemia were associated with a lower possibility of normoglycemia reversion. In contrast, obesity, current smoking, and hypertension increased the risk of type 2 diabetes. Consistent with findings of previous studies, high BMI and waist circumference–defined abdominal obesity were inversely associated with reversion to normoglycemia (14,27,30) and positively associated with progression to diabetes (30,31). The presence of hypertension was associated with a lower possibility of normoglycemia reversion and a higher possibility of type 2 diabetes progression. Authors of a previous study reported a similar finding that showed a lower likelihood of reversion to normoglycemia among people with hypertension, using the same definition of glycemic status that we used in the present study (27). Furthermore, other previous studies using the ADA criteria of HbA1c-defined prediabetes likewise found that hypertension in people with prediabetes increased the risk of developing type 2 diabetes mellitus (31,32), especially those whose HbA1c values were higher (32).

A healthy lifestyle is beneficial for preventing diseases. Previous studies have shown that adherence to a healthier lifestyle is associated with a lower risk of developing type 2 diabetes (33,34). Correspondingly, the findings of the present study also imply that individuals who adhered to more healthy or favorable modifiable factors were less likely to progress to diabetes. To our knowledge, no study has reported the association of lifestyle or modifiable-factors scores with reversion to normoglycemia among people with prediabetes. As for the findings from the present study, people with prediabetes who had more favorable modifiable factors had a higher possibility of normoglycemia reversion. The results were consistent when either abdominal obesity or BMI was considered as one of the scoring components, indicating that either of these variables can be used to evaluate adherence to lifestyle factors or modifiable risk factors to promote normoglycemia reversion and prevent type 2 diabetes.

The strength of this study is that it was based on a large prospective study among the Korean population and included a scoring analysis of modifiable factors for normoglycemia reversion from prediabetes. However, this study had some limitations. First, the follow-up rate of participants in phase II was low (50.6%), which caused a large number of participants to be excluded from the study. However, our analysis indicated that those with follow-up data did not differ from those without follow-up data in terms of the measured characteristics critical to this study. Second, because some parts of the data were collected using a self-report questionnaire, there could be a possibility of bias in the collected information. Third, information regarding medication type was not assessed; thus, it was not possible to see the role of any type of medication in the glycemic status change among participants. However, people with a history of being diagnosed with diabetes by a physician were excluded from the study participants and this minimized the effect of diabetes medication use by participants in altering glycemic status change. Fourth, owing to the availability of biomarker information, the glycemic status in this study was only defined by two parameters. The oral glucose tolerance test results were not collected in the original cohort study; therefore, there could be other individuals with prediabetes who were not included. More studies regarding the glycemic status change among people with prediabetes are recommended to perform a wider range of analyses using all the markers of glycemic status definitions to provide more detailed evidence that could be useful in the future. A study to examine more comprehensive associations between sociodemographic factors and normoglycemia reversion is also suggested.

Conclusion

This study observed associations between modifiable risk factors and normoglycemia reversion, as well as type 2 diabetes progression, among people with prediabetes. The results showed that most participants remained in the prediabetes level at follow-up. Having more favorable modifiable factors was associated with a higher probability of returning to normoglycemia and a lower probability of progression to type 2 diabetes. These findings can be used as evidence to encourage the public, especially individuals with prediabetes, to engage in a healthier lifestyle and manage their weight and body composition, blood pressure, and lipid profiles to promote glycemic status reversion to the normal range and prevent type 2 diabetes progression.

This article contains supplementary material online at https://doi.org/10.2337/figshare.21743018.

Funding. This work was supported by the Ministry of Education of the Republic of Korea and the National Research Foundation of Korea (grants NRF-2018R1A2A3075397 and NRF-2022R1A2B5B01002471) and Korea Centers for Disease Control and Prevention (grants 2004-E71004-00, 2005-E71011-00, 2005-E71009-00, 2006-E71001-00, 2006-E71004-00, 2006-E71010-00, 2006-E71003-00, 2007-E71004-00, 2007-E71006-00, 2008-E71006-00, 2008-E71008-00, 2009-E71009-00, 2010-E71006-00, 2011-E71006-00, 2012-E71001-00, 2013-E71009-00, 2018-P7106-00, and 2021-E0608-00).

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. S.N. contributed to the study concept and design, data analysis and interpretation, manuscript drafting, and discussion. J.E.K., J.C., and J.P. contributed to data acquisition and discussion. A.S., S.-A.L., J.-k.L., and D.K. contributed to the article discussion. J.-Y.C. contributed to the study concept and design, manuscript drafting, and discussion, and is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

1.
American Diabetes Association Professional Practice Committee
.
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022
.
Diabetes Care
2022
;
45
(
Suppl. 1
):
S17
S38
2.
Hostalek
U
.
Global epidemiology of prediabetes - present and future perspectives
.
Clin Diabetes Endocrinol
2019
;
5
:
5
3.
International Diabetes Federation
.
IDF Diabetes Atlas, 10th ed
.
Accessed 16 May 2022. Available from https://www.diabetesatlas.org
4.
Kim
JH
,
Lim
JS
.
Trends of diabetes and prediabetes prevalence among Korean adolescents from 2007 to 2018
.
J Korean Med Sci
2021
;
36
:
e112
5.
Jung
CH
,
Son
JW
,
Kang
S
, et al
.
Diabetes Fact Sheets in Korea, 2020: an appraisal of current status
.
Diabetes Metab J
2021
;
45
:
1
10
6.
Xu
XY
,
Leung
AYM
,
Smith
R
,
Wong
JYH
,
Chau
PH
,
Fong
DYT
.
The relative risk of developing type 2 diabetes among individuals with prediabetes compared with individuals with normoglycaemia: meta-analysis and meta-regression
.
J Adv Nurs
2020
;
76
:
3329
3345
7.
Cai
X
,
Zhang
Y
,
Li
M
, et al
.
Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis
.
BMJ
2020
;
370
:
m2297
8.
Cai
X
,
Liu
X
,
Sun
L
, et al
.
Prediabetes and the risk of heart failure: a meta-analysis
.
Diabetes Obes Metab
2021
;
23
:
1746
1753
9.
Huang
Y
,
Cai
X
,
Qiu
M
, et al
.
Prediabetes and the risk of cancer: a meta-analysis
.
Diabetologia
2014
;
57
:
2261
2269
10.
American Diabetes Association Professional Practice Committee
.
3. Prevention or delay of type 2 diabetes and associated comorbidities: standards of medical care in diabetes-2022
.
Diabetes Care
2022
;
45
(
Suppl. 1
):
S39
S45
11.
Perreault
L
,
Pan
Q
,
Schroeder
EB
, et al.;
Diabetes Prevention Program Research Group
.
Regression from prediabetes to normal glucose regulation and prevalence of microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS)
.
Diabetes Care
2019
;
42
:
1809
1815
12.
Perreault
L
,
Temprosa
M
,
Mather
KJ
, et al.;
Diabetes Prevention Program Research Group
.
Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program Outcomes Study
.
Diabetes Care
2014
;
37
:
2622
2631
13.
Vistisen
D
,
Kivimäki
M
,
Perreault
L
, et al
.
Reversion from prediabetes to normoglycaemia and risk of cardiovascular disease and mortality: the Whitehall II cohort study
.
Diabetologia
2019
;
62
:
1385
1390
14.
Kowall
B
,
Rathmann
W
,
Kuss
O
, et al
.
Reversion from prediabetes to normoglycaemia after weight change in older persons: the KORA F4/FF4 study
.
Nutr Metab Cardiovasc Dis
2021
;
31
:
429
438
15.
Paprott
R
,
Scheidt-Nave
C
,
Heidemann
C
.
Determinants of change in glycemic status in individuals with prediabetes: results from a nationwide cohort study in Germany
.
J Diabetes Res
2018
;
2018
:
5703652
16.
Bennasar-Veny
M
,
Fresneda
S
,
López-González
A
,
Busquets-Cortés
C
,
Aguiló
A
,
Yañez
AM
.
Lifestyle and progression to type 2 diabetes in a cohort of workers with prediabetes
.
Nutrients
2020
;
12
:
1538
17.
Hur
KY
,
Moon
MK
,
Park
JS
, et al.;
Committee of Clinical Practice Guidelines, Korean Diabetes Association
.
2021 Clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association
.
Diabetes Metab J
2021
;
45
:
461
481
18.
World Health Organization
.
Noncommunicable disease
.
19.
Health Examinees Study Group
.
The Health Examinees (HEXA) study: rationale, study design and baseline characteristics
.
Asian Pac J Cancer Prev
2015
;
16
:
1591
1597
20.
Kim
Y
;
KoGES group
.
Cohort profile: The Korean Genome and Epidemiology Study (KoGES) Consortium
.
Int J Epidemiol
2017
;
46
:
1350
21.
Choi
J
,
Choi
JY
,
Shin
A
, et al
.
Trends and correlates of high-risk alcohol consumption and types of alcoholic beverages in middle-aged Korean adults: results from the HEXA-G Study
.
J Epidemiol
2019
;
29
:
125
132
22.
Lim
J
,
Lee
Y
,
Shin
S
, et al
.
An association between Diet Quality Index for Koreans (DQI-K) and total mortality in Health Examinees Gem (HEXA-G) study
.
Nutr Res Pract
2018
;
12
:
258
264
23.
Kim
BY
,
Kang
SM
,
Kang
JH
, et al.;
Committee of Clinical Practice Guidelines, Korean Society for the Study of Obesity (KSSO)
.
2020 Korean Society for the Study of Obesity Guidelines for the Management of Obesity in Korea
.
J Obes Metab Syndr
2021
;
30
:
81
92
24.
International Diabetes Federation
.
The IDF consensus worldwide definition of the metabolic syndrome
.
25.
Yang
D
,
Dalton
JE
.
A unified approach to measuring the effect size between two groups using SAS
.
26.
West
SL
,
Gartlehner
G
,
Mansfield
AJ
, et al
.
Comparative Effectiveness Review Methods: Clinical Heterogeneity
.
Report No.: 10-EHC070-EF
.
Rockville, MD
:
Agency for Healthcare Research and Quality
;
September
2010
.
27.
Lazo-Porras
M
,
Bernabe-Ortiz
A
,
Ruiz-Alejos
A
, et al
.
Regression from prediabetes to normal glucose levels is more frequent than progression towards diabetes: the CRONICAS Cohort Study
.
Diabetes Res Clin Pract
2020
;
163
:
107829
28.
Shang
Y
,
Marseglia
A
,
Fratiglioni
L
, et al
.
Natural history of prediabetes in older adults from a population-based longitudinal study
.
J Intern Med
2019
;
286
:
326
340
29.
Rooney
MR
,
Rawlings
AM
,
Pankow
JS
, et al
.
Risk of progression to diabetes among older adults with prediabetes
.
JAMA Intern Med
2021
;
181
:
511
519
30.
Blume
SW
,
Li
Q
,
Huang
JC
,
Hammer
M
,
Graf
TR
.
Variation in the risk of progression between glycemic stages across different levels of body mass index: evidence from a United States electronic health records system
.
Curr Med Res Opin
2015
;
31
:
115
124
31.
Li
N
,
Lu
C
,
Ma
Y
, et al
.
Factors associated with progression of different prediabetic status to diabetes: a community-based cohort study
.
Diabetes Res Clin Pract
2022
;
184
:
109193
32.
Jung
JY
,
Oh
CM
,
Ryoo
JH
, et al
.
The influence of prehypertension, hypertension, and glycated hemoglobin on the development of type 2 diabetes mellitus in prediabetes: the Korean Genome and Epidemiology Study (KoGES)
.
Endocrine
2018
;
59
:
593
601
33.
Song
Z
,
Yang
R
,
Wang
W
, et al
.
Association of healthy lifestyle including a healthy sleep pattern with incident type 2 diabetes mellitus among individuals with hypertension
.
Cardiovasc Diabetol
2021
;
20
:
239
34.
Li
H
,
Khor
CC
,
Fan
J
, et al
.
Genetic risk, adherence to a healthy lifestyle, and type 2 diabetes risk among 550,000 Chinese adults: results from 2 independent Asian cohorts
.
Am J Clin Nutr
2020
;
111
:
698
707
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license.